Learn › Weight Loss

Zepbound vs. Wegovy Cost: Which Is More Affordable in 2025?

By Truventa Medical Clinical Team · Updated April 2025 · 8 min read

Zepbound and Wegovy are the two most effective FDA-approved weight loss medications available in 2025 — but both carry price tags that make most patients' eyes water. With retail prices hovering around $1,000–$1,400 per month, the cost difference between these two drugs matters enormously over a year or more of treatment. Here's a complete, honest comparison of Zepbound vs. Wegovy cost in 2025, including insurance coverage, manufacturer savings programs, and the compounded alternatives that make these treatments accessible for far less.

Retail Price: Zepbound vs. Wegovy in 2025

Let's start with the numbers. At U.S. pharmacy retail price in 2025:

• Wegovy (semaglutide 2.4 mg) — manufactured by Novo Nordisk — lists at $1,349.02 per month for a 4-pen supply, regardless of dose tier
• Zepbound (tirzepatide) — manufactured by Eli Lilly — has a more complex pricing structure by dose: approximately $1,059–$1,086 per month for lower doses (2.5 mg, 5 mg) and $1,059–$1,086 for higher doses (10 mg, 12.5 mg, 15 mg). Lilly has kept Zepbound's pricing more consistent across doses than some expected.

On retail price alone, Zepbound is meaningfully cheaper than Wegovy — by roughly $250–$290 per month. That's a savings of $3,000–$3,500 per year if you're paying cash price. However, this comparison gets much more nuanced when you factor in insurance coverage and savings programs.

For a detailed clinical comparison of the two medications, see our guide on Wegovy vs. Zepbound.

Insurance Coverage: Which Drug Gets Covered More?

Insurance coverage is where the Zepbound vs. Wegovy cost comparison gets complicated. Neither drug is universally covered, and the insurance landscape for obesity medications is still evolving rapidly in 2025.

General Coverage Landscape

As of 2025, approximately 40–55% of large employer-sponsored commercial health plans cover at least one GLP-1 weight loss medication. However, formulary choices vary dramatically between insurers and employers. Some plans cover Wegovy but not Zepbound; others cover both; many cover neither for weight loss specifically.

Wegovy Insurance Coverage

Wegovy has had more time on the market (FDA-approved June 2021) and has been on formularies longer. Key insurance points:

• More formulary entries due to longer market presence
• Covered by some Medicare Part D plans specifically for patients with cardiovascular disease (ASCVD indication added 2024)
• Requires BMI ≥30 or ≥27 with qualifying comorbidity on most plans
• Step therapy and prior authorization are common hurdles

Zepbound Insurance Coverage

Zepbound (FDA-approved November 2023) is newer, which means fewer plans have had time to add it to formularies. However, coverage is expanding quickly:

• Rapid formulary additions through 2024–2025 as Lilly aggressively negotiated with PBMs
• Zepbound also now has FDA approval for obstructive sleep apnea in obese patients — potentially expanding coverage indications
• Not yet covered by Medicare for weight loss alone (same restriction as Wegovy)
• More plans in 2025 are choosing one or the other (Wegovy or Zepbound), not both — your plan may specify which is preferred

Bottom line on insurance: There's no universal winner. The drug that costs you less depends entirely on what your specific insurance plan covers. Before assuming either is "covered," call your insurer and ask specifically about formulary tier and prior authorization requirements for both medications.

Manufacturer Savings Programs: Lilly vs. Novo Nordisk

Novo Nordisk Wegovy Savings Card

Novo Nordisk's savings card for Wegovy can reduce copays to as low as $0 per month for up to 13 months for eligible commercially insured patients. Key restrictions:

• Must have commercial insurance that covers Wegovy (not available for uninsured or government insurance)
• Applies to your copay/coinsurance only — your insurance must still agree to pay
• Resets or requires reapplication after 13 months
• Annual maximum savings cap applies
• Not valid for Medicare or Medicaid beneficiaries

Eli Lilly Zepbound Savings Program + Lilly Direct

Eli Lilly has taken a more innovative approach to affordability with Zepbound, offering two separate programs:

Lilly Savings Card (for insured patients): Similar to Novo Nordisk's program, Lilly's savings card can reduce Zepbound copays to as low as $25 per month for commercially insured patients. This is a great benefit, though the floor copay ($25) is slightly higher than Wegovy's theoretical $0 floor.

Lilly Direct (for uninsured patients): This is genuinely groundbreaking. Lilly launched a direct-to-consumer program allowing uninsured patients to purchase Zepbound vials (not pens) directly from Lilly at $399/month for lower doses (2.5 mg, 5 mg) and $549/month for higher doses (7.5 mg, 10 mg, 12.5 mg, 15 mg). This is available only through the LillyDirect portal with a prescription.

The Lilly Direct self-pay vial program is a significant advantage for Zepbound over Wegovy in terms of accessibility for uninsured patients. Novo Nordisk has not launched a comparable direct-to-consumer program for Wegovy. At $399–$549/month through Lilly Direct, Zepbound becomes meaningfully more accessible than Wegovy's $1,349 retail price for uninsured patients.

12-Month Cost Comparison: Zepbound vs. Wegovy

Scenario	Wegovy (12 mo)	Zepbound (12 mo)	Winner
No insurance, retail price	~$16,188	~$12,708	Zepbound (−$3,480)
No insurance, direct program	N/A	$4,788–$6,588	Zepbound (only option)
Insured, savings card ($0/$25 copay)	$0–$300	$300	Wegovy (slightly)
Insured, Tier 4 specialty copay	$1,800–$3,600	$1,800–$3,600	Roughly equal
Compounded (semaglutide or tirzepatide)	See Truventa pricing — dramatically less than either brand		Compounded wins

Which Is Covered by More Insurance Plans?

Based on available formulary data in 2025, Wegovy still holds a marginal lead in overall insurance plan coverage due to its earlier FDA approval and longer negotiation history. However, Zepbound is closing this gap rapidly.

Importantly, some insurers are now selecting either Wegovy or Zepbound as their preferred GLP-1 weight loss drug and excluding the other. If your plan covers only one, that's the one that's affordable — the other could cost you $16,000+/year even if it's "technically available."

The practical advice: check your specific plan before your doctor writes a prescription. This can save enormous hassle and cost. Your insurer's pharmacy hotline or benefits portal will tell you exactly which medications are on formulary, what prior auth is required, and what your expected copay would be.

Compounded Alternatives: The Most Affordable Option for Either Drug

Both Wegovy (semaglutide) and Zepbound (tirzepatide) have compounded alternatives available through telehealth providers like Truventa Medical. Compounded versions contain the same active pharmaceutical ingredients but are prepared by FDA-registered compounding pharmacies at a fraction of the brand-name cost.

For patients without insurance coverage — or with coverage that still leaves a high monthly copay — compounded semaglutide and compounded tirzepatide represent by far the most cost-effective paths to GLP-1 treatment. Even Lilly Direct's $399/month Zepbound vials cost substantially more than compounded options available through telehealth.

The clinical considerations are the same as with brand-name versions: the same active ingredient, the same mechanism of action, and a provider-supervised dosing and titration protocol. The main difference is price. See our pricing page for current compounded GLP-1 costs at Truventa.

Which Should You Choose?

Beyond cost, the clinical evidence slightly favors Zepbound. The SURMOUNT-5 trial (2025) directly compared tirzepatide vs. semaglutide head-to-head and found tirzepatide produced significantly greater weight loss: approximately 20% average body weight reduction vs. 14% for semaglutide at 72 weeks. This is largely due to tirzepatide's dual mechanism — it activates both GLP-1 and GIP receptors.

However, semaglutide (Wegovy) has a longer track record, more published safety data, and may be better tolerated in patients who experience GI side effects with tirzepatide. For some patients, the older drug remains the right choice.

Our recommendation: let your insurance coverage and clinical profile guide the choice, not brand loyalty. If your plan covers Wegovy but not Zepbound, that's a clear financial signal. If you're uninsured, Lilly Direct or compounded tirzepatide likely offers the best value. If you're evaluating clinically, discuss with a provider which mechanism suits your health profile.